novo nordisk oral glp 1 Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients With FDA approval of Wegovy

Doses above 1.0mg cause spillover binding to MC3R and MC4R receptors, triggering nausea, spontaneous erections in males, and darkening of existing nevi

Retrieved from JAMA Network

Researchers compared the percentage of body weight loss after 3, 6, 9 and 12 months of treatment among adults who received intensive lifestyle modification, non-GLP-1 receptor agonist pharmacotherapy or GLP-1 receptor agonists as part of a weight-loss program, with both pharmacotherapy groups also utilizing intensive lifestyle modification

Glutathione doesnt just act in one way

Finkelstein J, Martin J: Methionine metabolism in mammals: distribution of homocysteine between competing pathways